
News|Articles|July 1, 2003
Pharmaceutical marketing practices and generic drugs in the spotlight
Author(s)Jill Wechsler
Formulary committees, pharmacy benefit managers (PBMs), pharmacists, and physicians face increased scrutiny of their relationships with pharmaceutical manufacturers under a final fraud policy statement from the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid tech companies pledge $600 million to help states update systems
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5























